Ergogenic effects of new-generation beta2-agonists vilanterol and indacaterol

Code: 21C20VB

This project aims to determine whether new-generation ultra long-acting beta2-agonist (U-LABA) formulations containing vilanterol and indacaterol can enhance performance when inhaled at therapeutic or supratherapeutic doses in highly-trained males and females. The project will also examine whether U-LABA can induce muscle hypertrophy when used chronically.

Objectives: This project will investigate the potential performance-enhancing effects of vilanterol and indacaterol at therapeutic and supratherapeutic inhaled doses. THe formulations tested are Relvar® (22 µg/dose vilanterol+fluticasone 55 µg/dose) and Atectura® (indacaterol 125 µg/dose+mometasone 62 µg/dose) as these are U-LABA formulations of relevance for asthma treatment.